BTIG Research Increases Xtant Medical (NYSEAMERICAN:XTNT) Price Target to $3.00

Xtant Medical (NYSEAMERICAN:XTNT) had its target price upped by BTIG Research from $2.00 to $3.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the medical device company’s stock. BTIG Research’s target price would indicate a potential upside of 316.61% from the stock’s previous close.

Xtant Medical Price Performance

XTNT opened at $0.72 on Thursday. The stock has a market cap of $93.77 million, a price-to-earnings ratio of -72.01 and a beta of 0.30. The company has a quick ratio of 1.22, a current ratio of 2.82 and a debt-to-equity ratio of 0.34. Xtant Medical has a 52 week low of $0.60 and a 52 week high of $1.45.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings results on Wednesday, May 15th. The medical device company reported ($0.03) earnings per share for the quarter. The firm had revenue of $27.87 million for the quarter. Xtant Medical had a negative net margin of 1.64% and a negative return on equity of 3.64%.

Institutional Investors Weigh In On Xtant Medical

Several institutional investors have recently modified their holdings of XTNT. AMH Equity Ltd purchased a new position in Xtant Medical in the 3rd quarter worth about $653,000. AWM Investment Company Inc. bought a new position in Xtant Medical during the 3rd quarter worth about $516,000. Juniper Investment Company LLC purchased a new position in Xtant Medical during the 1st quarter valued at about $408,000. Vanguard Group Inc. raised its holdings in shares of Xtant Medical by 3.2% in the 1st quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company’s stock valued at $1,812,000 after purchasing an additional 48,319 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. purchased a new stake in shares of Xtant Medical in the 3rd quarter worth approximately $38,000. 69.33% of the stock is owned by institutional investors.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.